



EP05.05: Lung Cancer and Tuberculosis: Current Research Status and Future Directions-A Bibliometric Analysis Based on the Web of Science Database



IASLC 2026 World
Conference on Lung Cancer
SEPTEMBER 12 - 15, 2026
SEOUL, REPUBLIC OF KOREA

Shi Li¹, Yanglei Zhang², Weijie Shang¹, Yanping Liu¹, Haolong Zheng¹, Wentong Jiang¹, Xuefei Guo¹, Lihui Song¹
¹Department of Medical Oncology, Shenyang The Tenth People's Hospital, Shenyang, China, ²Department of Respiratory, Shenyang The Tenth People's Hospital, Shenyang, China.
Correspondence: 198321lishi@163.com

INTRODUCTION

This study aims to delineate the research landscape and emerging hotspots in the field of lung cancer and tuberculosis, providing references for clinical practice and scientific research.

METHODS

A search was conducted in the Web of Science Core Collection using the query: Tubercul* (Topic) and "lung cancer" (Topic). Bibliometric analysis was performed using CiteSpace 7.0.R0.

DISCUSSION AND CONCLUSION

Research on lung cancer and tuberculosis is rapidly evolving from traditional approaches centered on differential diagnosis and comorbidity management toward an integrated precision medicine paradigm driven by deep learning, immunotherapy, and systems biology.

A total of 2,309 publications were included, spanning 955 journals, 12,948 authors, 7,774 institutions, and 381 countries/regions. Annual publication output increased steadily from 2000 to 2025, with 192 papers published in 2025 and 37 in 2026. The most prolific author, institution, and country were Aggarwal, Ashutosh N (8 papers), Seoul National University (34 papers), and the People's Republic of China (590 papers). The institutions and countries with the highest betweenness centrality were the University of London (0.07) and England (0.21). Highly cited authors and journals included LIANG HY and CHEST. Using LSI and LLR algorithms, key keyword clusters were identified as: #0 copd epidemiology / smoking; #1 transbronchial biopsy / endobronchial ultrasound; #2 immune checkpoint inhibitor / pleural effusion; #3 systems biology / lung cancer; #4 polymersomes / respiratory diseases; #5 clinical diagnosis / deep learning; #6 pd-1 inhibitor / nivolumab; #7 atypical mycobacterial infection / non hodgkins lymphoma; #8 gastric cancer / pneumonectomy; #9 lung carcinoma / pulmonary tuberculoma; #10 mobile helical computed tomography / aortic calcification.

RESULTS

